• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

M&A

Graphic of a puzzle depicting both the US and Chinese flags with missing pieces bridging the two together
Biotech

Treasury COINS rules add biotech, spares China licensing deals

Despite the sweeping scope of the ban covering various drug modalities, biopharma business development teams can breathe a measured sigh of relief.
Angus Liu Oct 22, 2026 11:36pm
A graphic symbolizing one group acquiring another

Lexeo acquires Mantle for $8M, adding Friedreich ataxia assets

Sep 22, 2026 9:58am
heart over ekg

Newly formed Jaguar acquires Afib device assets from J&J

Sep 15, 2026 11:11am
Novartis Switzerland
Favicon Fierce Pharma

Novartis investor calls for board overhaul after costly setbacks

Sep 10, 2026 10:26am
Graphic image of two hands shaking with employeesexecutives on the forearms of each shaking hand

Fortrea boosts early-phase platform with $45M acquisition

Sep 2, 2026 3:06pm
MA combine

Skye and Redx combine with $125M to advance fibrosis assets

Aug 14, 2026 2:05pm

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings